- Short report
- Open Access
Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma
Biomarker Researchvolume 1, Article number: 14 (2013)
The cyclin-dependent kinase inhibitor p27Kip1 functions during normal cerebellar development and has demonstrated tumor suppressor functions in mouse models of medulloblastoma. Because P27 loss is associated with increased proliferation, we assessed whether P27 absence in surgical medulloblastoma specimens correlated with response to therapy in pediatric patients enrolled in two large studies. Additionally, we examined the functional consequence of p27Kip1 loss in the SmoA1 medulloblastoma model to distinguish whether p27Kip1 reduces tumor initiation or slows tumor progression.
Analysis of 87 well-characterized patient samples identified a threshold of P27 staining at which significant P27 loss correlated with poor patient outcome. The same criteria, applied to a second test set of tissues from 141 patients showed no difference in survival between patients with minimal P27 staining and others, suggesting that P27 levels alone are not a sufficient prognostic indicator for identifying standard-risk patients that may fail standard therapy. These findings were in contrast to prior experiments completed using a mouse medulloblastoma model. Analysis of cerebellar tumor incidence in compound mutant mice carrying the activated Smoothened (SmoA1) allele that were heterozygous or nullizygous for p27Kip1 revealed that p27Kip1 loss did not alter the frequency of tumor initiation. Tumors haploinsufficient or nullizygous for p27Kip1 were, however, more invasive and displayed a higher proliferative index, suggesting p27Kip1 loss may contribute to SmoA1 medulloblastoma progression.
These studies revealed P27 loss affects medulloblastoma progression rather than initiation and that this putative biomarker should not be used for stratifying children with medulloblastoma to risk-based therapeutic regimens.
Approximately 20% of medulloblastoma patients classified as standard risk fail therapy and succumb to their disease . Current prognostic criteria stratify patients into standard- or high-risk groups based upon age, the extent of surgical resection and the presence or absence of disseminated disease . The intensity of radio- and chemotherapy are determined by risk group, although significant impairments induced by current strategies are well established, particularly in younger patients [2, 3]. Because of these devastating toxicities, efforts are underway to reduce therapy intensity for standard risk patients. As the pediatric neuro-oncology community begins to de-escalate standard risk therapy, it consequently becomes critically important to identify molecular markers that recognize children likely to fail therapy that would benefit from stratification to more intensive therapeutic regimens.
Studies in various mouse models have demonstrated that loss of a single p27Kip1 [GenBank: NM_009875] allele increases tumor formation, suggesting p27Kip1 ’s tumor suppressor function is haploinsufficient or acts in a dosage-dependent manner . In the SmoA1 mouse medulloblastoma model, loss of P27 resulted in early death compared to counterparts with wildtype P27 levels . While this work showed that P27 has tumor suppressive function in medulloblastoma, it remained to be determined whether loss of P27 caused an increase in tumor initiation or progression. This is an important distinction because molecules involved in tumor initiation are rarely good prognostic indicators, whereas a subset of molecules involved in tumor progression reliably predict response to therapy.
While p27Kip1mutations are generally rare, P27 abundance has provided a reliable prognostic marker for cancer progression in a subset of human cancers, such as breast, colon and prostate [6, 7]. The prognostic value of P27 expression in human medulloblastoma is currently unknown. Previous studies using 14 human medulloblastoma samples found low or absent P27 expression in highly proliferative and undifferentiated tumor regions [8, 9], but the sample size was too small to assess prognostic value.
This study first addresses the unanswered question regarding P27’s role in tumor initiation versus progression in experiments conducted in a genetically engineered mouse medulloblastoma model. This study additionally assesses P27’s potential as a prognostic indicator in children with medulloblastoma. The study evaluates whether clinical outcomes improve for children with high P27 first in a retrospective clinical trial cohort (training data set) and then in a larger clinical trial cohort (test data set).
Compound mutant mice
SmoA1 mice were crossed with heterozygous p27wt/- mice to produce compound mutant (SmoA1, p27wt/- and SmoA1, p27−/−) mice. Mice were sacrificed at 2 months to examine tumor incidence via histopathology. Transgenic mice were maintained in accordance with the NIH Guide for the Care and Use of Experimental Animals with approval from our Institutional Animal Care and Use Committee.
Mice were pulsed with BrdU (100 mg/kg) one hour prior to sacrifice. Tissues were paraffin embedded and cut into four micron sections. Sagittal sections were cut at multiple levels from each cerebellum analyzed and scored for the presence or absence of tumor formation. Tissue sections were stained with antibodies recognizing p27, cyclin D1 and BrdU, and five high power fields (HPF) were scored for each sample to quantify the proliferative index within cerebellar tumors. Human medulloblastoma tissues were stained with a monoclonal p27Kip1 antibody and detection carried out with 3,3’-diaminobenzidine reagent. Tissue microarrays containing tissues from 87 patient samples were previously described . P27 protein expression levels were also examined on tissue microarrays containing tissues from 141 patients enrolled on the SIOP PNET03 (1992–2000) study [11, 12]. Staining intensity was evaluated by observers blinded to patient and survival data using the Nikon Elements Imagining Software after slides were digitally scanned.
For mouse studies, sagittal sections were cut at multiple levels from each cerebellum analyzed to evaluate tumor incidence and a Fisher’s exact test was used to determine p values. A t test was used to determine p values for quantification of the proliferative index. For human patients, overall survival was calculated from diagnosis date until death or the last follow up date. Survival distribution was estimated by the Kaplan-Meier method and compared using the log-rank test (SPSS 15.0). A multivariate Cox proportional-hazards regression model, with overall survival as the dependent variable, was used to assess the impact of P27 expression levels on the three individual components of the current risk stratification model (metastasis, residual disease, age <3). Two-sided p-values of less than 0.05 using the 95% confidential interval were considered to indicate statistical significance.
Genetic alterations have been isolated from medulloblastomas within signaling pathways that normally regulate proliferation and differentiation of granule neuron progenitors (GNPs) during cerebellar development . Medulloblastomas are induced in the SmoA1 mouse model through the constitutive activation of the sonic hedgehog (Shh) [GenBank: NM_009170] pathway within GNPs, signaling normally required for GNP proliferation. p27Kip1 loss in mice can increase tumor formation , and p27Kip1 haploinsufficiency has been further supported by studies using the Patched1 [GenBank: NM_008957] heterozygous (Ptc1+/−) and SmoA1 mouse medulloblastoma models [5, 14], where Shh-induced medulloblastoma incidence was accelerated by loss of one or both p27Kip1 alleles.
To determine whether p27Kip1 loss affected medulloblastoma initiation or progression, we generated mice hemizygous for the SmoA1 transgene that were heterozygous (p27wt/-) or nullizygous for p27Kip1 (p27−/−) and examined tumor incidence at two months of age, a time point preceding symptomatic medulloblastoma onset. Tumor incidence was 71.4% in SmoA1, p27wt/wt mice (n = 35); 73.1% in SmoA1, p27wt/- mice (n = 52); and 60% in SmoA1, p27−/− mice (n = 20). The differences were not significant (p = 1.0 and p = 0.55, respectively). Tumors from heterozygous SmoA1, p27wt/- mice did, however, display significantly more invasive phenotypes (Figure 1). 60.5% of SmoA1, p27wt/- mice had invasive tumors and tumors with effacement compared to 36.0% of SmoA1, p27wt/wt mice (Figure 2A, p = 0.04). Similarly, 66.7% of SmoA1, p27−/− mice displayed invasive and effaced pathology (Figure 2A, p = 0.08). The proliferative index, measured by bromodeoxyuridine (BrdU) incorporation, was higher in tumors with invasive or effaced pathology and greater in advanced tumors from SmoA1 mice lacking a single or both p27Kip1 alleles than in tumors from SmoA1, p27wt/wt mice (Figure 2B, p = 0.05 and p = 0.0001, respectively). Increased tumor progression was associated with decreased p27Kip1 and increased cyclinD1 [GenBank: NM_009829] protein levels in tumors from both study groups (Figure 2C-D).
An important observation can be drawn from comparing tumor incidence at two months to the survival at later time point results reported previously. Early tumor formation was relatively unchanged by the loss of a single or of both p27Kip1 alleles in our study. In contrast, SmoA1 mice with wildtype p27Kip1 lived on average twice as long as mice with a single copy of p27Kip1 , and mice retaining wildtype p27Kip1 in the heterozygous (Ptc1+/−) background survived significantly longer than counterparts lacking p27Kip1 , which succumbed due to an increased tumor incidence . In combination with the aggressive pathology observed in early tumors from SmoA1 mice lacking p27Kip1, the higher tumor incidence in Ptc1+/− mice lacking p27Kip1 further confirms that p27Kip1 is haploinsufficient in Shh-mediated medulloblastomas and that its loss of function contributes to medulloblastoma progression.
We next assessed whether P27 levels could distinguish children likely to fail therapy from those likely to be long-term survivors. To properly evaluate P27 as a potential marker of therapeutic response, we established quantitative criteria for P27 staining in a training set of patient samples then applied the same criteria to a larger test set. Human medulloblastoma tissue microarrays containing tissues from 87 patient samples were analyzed for P27 expression . 80% of samples evaluated had 20% or fewer P27 positive cells, with 16% of samples having less than 1% P27 positive cells. In contrast, intensity scoring of control sections from normal human cerebella revealed an average of 74% P27-positive granule cells (Figure 3A). Additional P27 staining on individual human medulloblastoma sections from five patients revealed significant loss of P27 protein (Figure 3B). Two tumor samples with regions lacking P27 contained additional regions resembling the remaining normal cerebellar architecture that stained positive for P27 (Figure 3C). Overall survival analysis demonstrated that patients with very low P27 expression had a poor outcome. Significant correlations were found when patients were stratified between high and low P27 levels, with patients with higher P27 levels (>1% P27 positive cells) having a more favorable outcome (n = 79, p = 0.027, data not shown). This correlation persisted when patients were additionally stratified by factors that define the standard-risk subgroup. P27 expression had prognostic value in patients greater than three years old with total surgical resection (n = 30, p = 0.001) or a lack of metastasis (n = 44, p = 0.007). While the number of patients with clinical data for all three standard-risk parameters was too small for Kaplan-Meier analysis, multivariate analysis with overall survival as the dependent variable demonstrated that P27 expression levels had prognostic value, independent of the extent of tumor resection or metastasis.
Together, these data suggested that P27 absence could further stratify standard-risk patients between survivors and those that fail therapy and do not survive. Because incorrect patient stratification could result in death for children placed improperly into a lower risk group, or unnecessary toxicity in children placed improperly into a higher risk group, we sought to confirm these findings by examining tissues from a second, larger study population. Tissues from 141 patient samples from children treated on the SIOP PNET03 clinical trial in Europe were stained for P27 and analyzed as above [11, 12]. Only two patients were identified that met the <1% cutoff criteria, indicating that the threshold established in the training set was not suitable for the test data set. To determine if this threshold was too stringent, we relaxed the criteria to <10% to capture more patients with low P27 expression. No significant differences were found in overall survival (P = 0.67) or in progression free survival (P = 0.55) between patients with little to no (less than 10%, F/N) P27 cells and those with greater than 10% P27 positive cells (M) (Figure 3D). We therefore conclude that the first test set was a false positive signal, likely due to small numbers and retrospective establishment of the cutoff criteria. This discrepancy underscores the importance of evaluating potential prognostic indicators in large patient populations and using both training and test data sets when developing candidate prognostic indicators for clinical use. To our knowledge, this is the first quantitative analysis of P27 expression in a large cohort of human medulloblastoma samples.
Granule neuron progenitor
Inner granule layer
High power field
Invasive with effacement
Non-invasive tumor with no effacement.
Gilbertson RJ: Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004, 5: 209–218. 10.1016/S1470-2045(04)01424-X
Carlotti CG Jr, Smith C, Rutka JT: The molecular genetics of medulloblastoma: an assessment of new therapeutic targets. Neurosurg Rev 2008, 31: 359–368. discussion 368–9 10.1007/s10143-008-0146-4
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006, 7: 813–820. 10.1016/S1470-2045(06)70867-1
Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998, 396: 177–180. 10.1038/24179
Bhatia B, Malik A, Fernandez-L A, Kenney AM: p27Kip1 , A double-edged sword in Shh-mediated medulloblastoma. Cell Cycle 2010, 9: 4307–4314. 10.4161/cc.9.21.13441
Blain SW, Scher HI, Cordon-Cardo C, Koff A: p27 As a target for cancer therapeutics. Cancer Cell 2003, 3: 111–115. 10.1016/S1535-6108(03)00026-6
Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW: p27kip1: a multifunctional cyclin dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999, 154: 313–323. 10.1016/S0002-9440(10)65277-7
Adesina AM, Dunn ST, Moore WE, Nalbantoglu J: Expression of p27kip1 and p53 in medulloblastoma: relationship with cell proliferation and survival. Pathol Res Pract 2000, 196: 243–250. 10.1016/S0344-0338(00)80073-4
Schiffer D, Bortolotto S, Bosone I, Cancelli I, Cavalla P, Schiffer P, Piva R: Cell-cycle inhibitor p27/Kip-1 expression in non-astrocytic and non-oligodendrocytic human nervous system tumors. Neurosci Lett 1999, 264: 29–32. 10.1016/S0304-3940(99)00171-8
de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L, Grajkowska W, Perek M, Osterheld MC, Ellison D, Baas F, Versteeg R, Kool M: Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res 2008, 14: 4154–4160. 10.1158/1078-0432.CCR-07-4159
Pizer BL, Weston CL, Robinson KJ, Ellison DW, Ironside J, Saran F, Pizer BL, Weston CL, Robinson KJ, Ellison DW, Ironside J, Saran F, Lashford LS, Tait D, Lucraft H, Walker DA, Bailey CC, Taylor RE: Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into SIOP/UKCCSG PNET 3 study. Eur J Cancer 2005, 42: 1120–1128.
Taylor RE, Bailey CC, Robinson KJ, Weston CL, Walker DA, Ellison D, Ironside J, Pizer BL, Lashford LS: Outcome for patients with metastatic (M2–3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 2005, 41: 727–734. 10.1016/j.ejca.2004.12.017
Marino S: Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 2005, 11: 17–22. 10.1016/j.molmed.2004.11.008
Ayrault O, Zindy F, Rehg J, Sherr CJ, Roussel MF: Two tumor suppressors, p27Kip1 and patched-1, collaborate to prevent medulloblastoma. Mol Cancer Res 2009, 7: 33–40. 10.1158/1541-7786.MCR-08-0369
We thank Julio Vasquez from the Fred Hutchinson Cancer Research Center (FHCRC) Scientific Imaging Core for assistance with tissue microarray imaging, the FHCRC Shared Resources Histopathology for assistance with tissue processing, Michael LeBlanc for assistance with statistical analysis and Sally Ditzler, Barbara Pullar, Keith Strand and Andrew Richards for assistance with transgenic animals.
NIH Grants CA112350-04, CA114567-03 and Children’s Hospital and Regional Medical Center Neuro-oncology Endowment Support (JMO) and a Bear Necessities Grant (BAH).
No authors of this paper have competing interests to disclose.
BAH conducted transgenic mouse studies and scored mouse pathology, immunohistochemically stained mouse and human tissue sections, participated in tissue imaging, data analysis and interpretation, and drafted and revised the manuscript. DWE, AG and MK provided tissue microarrays, assisted with data analysis and interpretation and assisted with manuscript revisions. MF provided transgenic animals, assisted with data interpretation and manuscript revisions. JMO provided transgenic animals, assisted with data interpretation and manuscript revisions. All authors read and approved the final manuscript.